Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Top Cited Papers
- 1 December 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 4 (12) , 988-1004
- https://doi.org/10.1038/nrd1902
Abstract
Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.Keywords
This publication has 162 references indexed in Scilit:
- A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancerNature Genetics, 2005
- Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathwayOncogene, 2004
- The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and diseaseJournal of Molecular and Cellular Cardiology, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Tuberous sclerosis genes regulate cellular 14-3-3 protein levelsBiochemical and Biophysical Research Communications, 2003
- Kinetic Analysis of Platelet-derived Growth Factor Receptor/Phosphoinositide 3-Kinase/Akt Signaling in FibroblastsPublished by Elsevier ,2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO)Leukemia, 2002
- The Hallmarks of CancerCell, 2000